World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) Guideline update - XIV - Recommendations on CMA immunotherapy
- Brozek, Jan L
- Firmino, Ramon T
- Bognanni, Antonio
- Arasi, Stefania
- Ansotegui, Ignacio
- Assa'ad, Amal H
- Bahna, Sami L
- Canani, Roberto Berni
- Bozzola, Martin
- Chu, Derek K
- Dahdah, Lamia
- Dupont, Christophe
- Dziechciarz, Piotr
- Ebisawa, Motohiro
- Galli, Elena
- Horvath, Andrea
- Kamenwa, Rose
- Lack, Gideon
- Li, Haiqi
- Martelli, Alberto
- Nowak-Węgrzyn, Anna
- Papadopoulos, Nikolaos G
- Pawankar, Ruby
- Roldan, Yetiani
- Said, Maria
- Sánchez-Borges, Mario
- Shamir, Raanan
- Spergel, Jonathan M
- Szajewska, Hania
- Terracciano, Luigi
- Vandenplas, Yvan
- Venter, Carina
- Waffenschmidt, Siw
- Waserman, Susan
- Warner, Amena
- Wong, Gary W K
- Fiocchi, Alessandro
- Schünemann, Holger J
DOIAbstract
The prevalence of cow's milk allergy (CMA) is approximately 2-4.5% in infants and less than 0.5% in adults. Most children outgrow cow's milk allergy in early childhood, particularly that to the baked milk products. Immunotherapy with unheated cow's milk has been used as a treatment option for those who have not yet outgrown CMA, but the benefits must be balanced with the adverse effects
Add to ORKG